Huizenga Theodore Alan's Form 4 filing
Ultragenyx Pharmaceutical Inc. (RARE) · filed Mar 5, 2024
- Accession no.
- 0000950170-24-026641
- Filed
- Mar 5, 2024
- Trade date
- Mar 1, 2024
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 3 non-derivative transactions and 2 derivative transactions. Open-market sales total $18.3K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Huizenga Theodore AlanCIK 0001603347 | Officer (SVP, Chief Accounting Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 1, 2024 | Common Stock | AGrant or awardAcquired | +13,950 | $0.00 | $0 | 41,842 | Direct | |
| Mar 1, 2024 | Common Stock | FTax withholdingDisposed | −121 | $53.69 | −$6,496.49 | 41,721 | Direct | |
| Mar 1, 2024 | Common Stock | SSaleDisposed | −341 | $53.76 | −$18,332.16 | 41,380 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 1, 2024 | Common Stock | AGrant or awardAcquired | +8,200 | $0.00 | $0 | 8,200 | Direct | |
| Mar 1, 2024 | Common Stock | AGrant or awardAcquired | +2,351 | $0.00 | $0 | 2,351 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.